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Objectives: In this study, the viral fitness of pseudo-viruses with a drug-resistant
site in the reverse transcriptase (RT) region of the genome was investigated. The
pseudo-viruses were derived from highly active antiretroviral therapy (HAART)-
experienced HIV/AIDS patients.
Methods: HIV-1 RNA was extracted from the plasma of HAART-experienced
(KRB9149, KRB7021, KRC1097) and HAART-naı¨ve (KRC5180, KRC5123) HIV-1
patients. The RT gene from the extracted viral RNA was amplified and the
polymerase chain reaction product was cloned from the pHXB2D2-261 RT vector.
C8166 and TZM-bl cell lines were used as the HIV-1 replication capacity
measurement system. To quantify the infectivity of homologous recombinant
HIV-1, the infectivity derived from each pseudo-virus was compared with the
infectivity of the reference strain HXB2.
Results: Patient-derived HIV-1 was cotransfected into C8166 cells and the
expression level of the p24 antigen was measured. The expression was high in
the HIV-1 isolates from patients KRC5180 and KRB9149 and low in patients
KRB7021, KRC5123, and KRC1097, when compared with the reference strain.
The infectivity of the pseudo-virus measured in TZM-bl cells decreased in the
order, reference strain HXB2 > KRC5180 > KRC5123 > KRB9149 > KRB7021 >
KRC1097.
Conclusion: In this study, HIV-1 infectivity of the drug-resistant strain isolated
from HAART-experienced patients with HIV/AIDS was found to be lower than the
infectivity of the reference strain HXB2. This study provides useful data for the
phenotypic susceptibility assay in HAART-experienced patients infected with
HIV-1.ibuted under the terms of the Creative Commons Attribution Non-Commercial License
y-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in
is properly cited.
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24 O.-K. Kwon, et al1. Introduction
The genetic variations of HIV-1 evolved in unique
directions influenced by antiretroviral drugs, and the
genetic or immunological characteristics of the host [1].
Therefore, it is expected that the virus clone adapted to
the environment may be evolved and disseminated
[2,3].
Antiretroviral drugs are one of the significant selec-
tion pressures that induce HIV-1 genetic variations.
Since the introduction of combination therapy in the
mid-1990s, antiretroviral drugs have contributed to the
decreased mortality of HIV/AIDS patients by control-
ling disease progression and extending their lives [4].
However, antiretroviral drug-resistant variants of the
virus have appeared among HIV/AIDS patients on
highly active antiretroviral therapy (HAART). These
drug-resistant variants also exhibit cross-resistance to
similar and sometimes different kinds of therapeutic
drugs. The control of drug resistance, therefore, has
become an important issue, not only in HAART-
experienced patients, but also in patients where treat-
ment has failed [5].
The prevalence of drug resistance of HAART-experi-
enced HIV/AIDS patients referred to the Korea National
Institute of Health for genotypic drug resistance tests was
20e30% between 2006 and 2007 in Korea [6]. After its
introduction in 1991, AZT (Zidovudine) has become
a widely used drug in Korea [7]. A national survey
showed that 20% of HAART-experienced HIV/AIDS
patients were resistant to AZT. Patients with variants
of the virus with D67N, T215Y or K219Q mutations
in the protein coded by the thymidine-related drug-
resistant gene, were found to be amongst those that
were most resistant [6]. Variants with dual resistance
against the protease (PR) and reverse transcriptase (RT)
regions have also appeared [6]. Therefore, it is neces-
sary to study the drug resistance and infectivity of
HIV-1 variants, to better understand the factors that
affect their dissemination.
In Korea, the drug resistance of clinical isolates has
been investigated by genotypic assay according to drug
treatment, viral load, and CD4 T cell counts [6].
However, these data are limited in their ability to analyze
some of the important factors for drug resistance. By
measuring HIV-1 p24 antigen production in HIV-1
infected cells or by measuring HIV-1 infectivity in
cells, the replication capacity of HIV-1 variants was
estimated and used to analyze drug resistance in the
variants. Silliciano et al reported various protocols that
can be used to measure the infectivity or replication
capacity in vitro by infecting the recombinant clones
with the whole or special region of the resistant gene
from clinical isolates [8,9].
In this study, the viral fitness of pseudo-viruses
derived from clinical isolates with drug-resistant sitesin the RT region of the HIV-1 genome in HAART-
experienced HIV/AIDS patients was investigated.2. Materials and Methods
2.1. Recombinant vector construction and
cotransfection
C8166 and TZM-bl cell lines were selected for the
HIV-1 replication capacity measurement system. The
pHXB2D2-261 RT vector (Stanford University, CA,
USA) was cultured using the TOPO TA cloning kit
(Invitrogen, CA, USA) and DNA was extracted using the
HiSpeed Plasmid Midi Kit (Qiagen, CA, USA). Trans-
formation was confirmed after treating with the restriction
enzyme SmaI. pHXB2D2-261 RT and the target gene
were transfected into C8166 cells with Lipofectamine
2000 (Invitrogen) and the cells were cultured at 37C in
5% CO2. To get a stable recombinant cell line, after
24 hours of transfection, the culture was scaled up to 6-
wells by dilution with 1:10 growth medium. After 7 days,
the culture medium containing the patient-derived virus
infected cells was collected and centrifuged at 400 g for
10 minutes. Supernatants of the C8166 cultured medium
were filtrated with 0.2 mm disposable syringe filters
(Nalgene, Rochester, NY, USA). HIV-1 isolates were
cotransfected with pHXB2D2-261 RT. The HIV-1 p24
antigen levels were measured twice using the supernatants
that had been cultured for 7e8 days after the infection.
2.2. HIV-1 RNA quantitation and
polymerization of HIV-1 pol gene
After extracting the RNA from the plasma using
the NucliSens Extractor (BioMerieux, Boxtel, The
Netherlands), viral load in blood was measured using
nucleic acid sequence-based amplification. The reverse
transcription polymerase chain reaction (RT-PCR) and
PCR conditions were based on the Stanford Center for
AIDS Research laboratory protocol for sequencing the
PR and RT parts of pol. RT-PCR and nested PCR were
performed as described earlier [7].
2.3. Analysis of predicted drug resistance
Sequencing of the HIV-1 pol gene was performed
using the ABI PRISMDye Terminator Cycle Sequencing
Ready Reaction kit (Perkin Elmer, MA, USA). The
sequences were analyzed with the Stanford HIV-SEQ
program, a HIV-1 drug resistance interpretation algo-
rithm, and the HIV-1 RT and PR sequence database to
focus on drug resistance-related mutation sites.
2.4. Infectivity measurement using TZM-bl cell
line
Viral supernatants (101, 1, 2, 5, 10, 20, 50, 100 mL)
were added to 24 hours pre-cultured cell with
a concentration of 104 cells/100 mL. The virus-exposed
Table. Characteristics of the patient-derived viral strains used to measure replication capacity and infectivity
Strain or patient Subtype
Drug resistance-related polymorphic sitesa/Drug resistance interpretation
PI NRTI NNRTI
Reference
(HXB2-IIIB)
B None/ None/ None/ Wild type
ATV(S), DRV(S), FPV(S), IDV(S),
LPV(S), NFV(S), SQV(S),
TPV(S)
3TC(S), ABC(S), AZT(S), D4T(S),
DDI(S), FTC(S), TDF(S)
DLV(S), EFV(S), ETV(S), NVP(S)
KRC5180 B None/ None/ None/ HAART naı¨ve/
primary patient
ATV(S), DRV(S), FPV(S), IDV(S),
LPV(S), NFV(S), SQV(S),
TPV(S)
3TC(S), ABC(S), AZT(S), D4T(S),
DDI(S), FTC(S), TDF(S)
DLV(S), EFV(S), ETV(S), NVP(S)
KRC5123 B None/ None/ None/ HAART naı¨ve
ATV(S), DRV(S), FPV(S), IDV(S),
LPV(S), NFV(S), SQV(S),
TPV(S)
3TC(S), ABC(S), AZT(S), D4T(S),
DDI(S), FTC(S), TDF(S)
DLV(S), EFV(S), ETV(S), NVP(S)
KRC1097 B None/ D67N, K70R, T215I, K219Q,
K103R/
None/ HAART experienced
ATV(S), DRV(S), FPV(S), IDV(S),
LPV(S), NFV(S), SQV(S),
TPV(S)
3TC(S), ABC(L), AZT(H), D4T(I),
DDI(L), FTC(S), TDF(L)
DLV(S), EFV(S), ETV(S), NVP(S)
KRB9149 B M46I, G48V, I50V, I54A, V82T/ M41L, L74I, V75T, V118I, M184V,
L210W, T215Y/
None/ HAART experienced
ATV(H), DRV(L), FPV(H),
IDV(H), LPV(H), NFV(H),
SQV(H), TPV(I)
3TC(H), ABC(H), AZT(H),
D4T(H), DDI(H), FTC(H),
TDF(I)
DLV(S), EFV(S), ETV(S), NVP(S)
KRB7021 B V32I, M46I, I47A, L90M/ M41L, D67N, V75M, V118I,
M184V, L210W, T215Y, K219N/
Y188L, K238Q/ HAART experienced
ATV(I), DRV(L), FPV(H), IDV(H),
LPV(H), NFV(H), SQV(I),
TPV(L)
3TC(H), ABC(H), AZT(H),
D4T(H), DDI(H), FTC(H),
TDF(I)
DLV(I), EFV(H), ETV(S), NVP(H)
aDrug resistance was estimated using the Stanford University Genotypic Resistance Algorithm (HIVdb).
HAART Z highly active antiretroviral therapy; NRTI Z nucleoside reverse transcriptase inhibitor; NNRTI Z non-nucleoside reverse transcriptase inhibitor; PI Z protease inhibitor; H Z High-level resistance;
I Z Intermediate resistance; L Z Low-level resistance; S Z Susceptible.
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26 O.-K. Kwon, et alcells were then cultured at 37C in 5% CO2 and 48 hours
after infection, ßegalactosidase activity was measured
using X-gal staining.Figure 1. Replication capacity of reference and patient strains
of HIV-1 in C8166 cells. NC1, NC2 and NC3 are the negative
controls for the patient-derived PCR products. NC1Z deletion
vector only; NC2 Z PCR product only; NC3 Z transfection
reagent without DNA; HXB2 Z reference strain; KRC5180
and KRC5123 Z HIV-1 strains from HAART-naı¨ve patients;
KRC1097, KRB9149 and KRB7021 Z HIV-1 strains from
HAART-experienced patients.3. Results
3.1. Genetic characteristics of the resistance
gene from clinical HIV-1 isolates
The HIV-1 isolates that were obtained from two
HAART-naı¨ve HIV/AIDS patients (KRC5180, KRC5123)
and three HAART-experienced patients (KRC1097,
KRB9149, KRB7021) out of the pool of samples sent
from hospitals to Korea National Institute of Health in
2006 requesting a genotypic assay of antiretroviral drug-
resistant variants are listed in the Table. All of five
clinical isolates of the HIV-1 strains were of the HIV-1
subtype B.
Based on the genotypic drug resistance assay, none of
the isolates from the HAART-naı¨ve patients (KRC5180,
KRC5123) were resistant to the antiretroviral drugs.
KRC5180, a patient with a primary infection, had
isolates that were protease inhibitors (PIs)-related minor
resistant variants like L10I and L63P. The isolates from
a HAART-experienced patient (KRC1097) had anti-
retroviral drug-resistant sites, similar to those for the
AZT-resistant reference strain (RTMC), at D67N,
K70R, T215I, and K219Q in the protein coded by the
thymidine-related drug-resistant gene. The isolates from
KRB9149 and KRB7021 were found to have anti-
retroviral drug resistance-related polymorphic sites
related to reverse transcriptase inhibitors (RTIs) resis-
tance at M41L, D67N, L74I, V75T/M, V118I, M184V,
L210W, T215Y, K219N, Y188L, and K238Q as well as
sites related to PIs-related resistance at M46I, G48V,
I50V, I54A, V82T, V32I, M46I, I47A, and L90M (see
the Table for details).Figure 2. Quantitative analysis of HIV-1 using X-gal stain-
ing for ßegalactosidase in TZM-bl indicator cell lines.
KRC5180 and KRC5123 Z HIV-1 strains from HAART-
naı¨ve patients; KRC1097, KRB9149 and KRB7021 Z HIV-1
strains from HAART-experienced patients. The reference
strain HXB2 was the positive control.3.2. Levels of p24 antigen in the homologous
recombinant HIV-1 pseudo-virus
propagated in the C8166 cell line
The levels of the p24 antigen of homologous
recombinant HIV-1 pseudo-viruses propagated using
C8166 cell lines compared with the level in the refer-
ence strain HXB2 are shown in Figure 1. Four of the five
isolates showed p24 levels following as; 65.56 pg/mL,
62.64 pg/mL, 55.64 pg/mL, and 52.37 pg/mL for
KRC5180, KRB9149, KRB7021, and KRC5123,
respectively. In comparison with reference strain HXB2
(61.87pg/mL), clinical isolates were in the similar range
(61.87 pg/mL  9.5pg/mL). However, the pseudo-virus
derived from KRC1097 showed a very low level of
p24 antigen production (8.02 pg/mL) (Figure 1). The
HIV-1 homologous recombinant virus has the RTI
resistance-related sites, D67N, K70R, T215I, K219Q
and K103R.3.3. Infectivity of the pseudo-virus derived from
a drug resistance-related mutant in TZM-bl
cells
Viral infectivity in TZM-bl cell lines was quantitated
using X-gal staining 48 hours after infection. The
infectivity of patient-derived pseudo-viruses, measured
using phenotypic assay, was compared with the HIV-1
reference strain HXB2 and the results are shown in
Figure 2. HXB2 had the highest infectivity, 4 
102  0.2 IFU/mL, followed by KRC5180 (2.6 
102  0.2 IFU/mL), KRC5123 (2.3  102  0.5 IFU/
mL), KRB7021 (1.5  102  0.7 IFU/mL), KRB9149
(0.8  102  0.3 IFU/mL), and KRC1097
(0.2  102  0.07 IFU/mL).4. Discussion
Many different methods have been used to measure
virus replication capacity [10,11]. Cell-based phenotypic
HIV-1 pseudo-virus from HAART-experienced patients 27assays help to determine the effect of viral variants on
antiretroviral drug resistance [12,13]. However, pheno-
typic assays are limited to measuring mixed HIV-1
variants with high resistance measurements and their
use in finding the resistance-related site is limited [14]. In
this study, the replication capacity of the HIV-1
recombinant virus derived from patients was measured
using homologous recombination [8]. The viral replica-
tion capacity has been measured using the expression
levels of the HIV-1 p24 antigen [15]. However, because
of the limitations of the phenotypic assay, measuring the
replication capacity using p24 antigen levels is restricted
to match the virus’s replication mechanism in the patient.
In the present study, the replication capacity or
infectivity of HIV-1 drug-resistant variants derived from
HAART-experienced patients was investigated to
understand the characteristics of drug-resistant strains
in Korea. Therefore, to estimate replication capacity,
p24 antigen levels were measured in recombinant cell
lines using clinical isolates from HAART-experienced
patients, HAART-naı¨ve patients and the reference strain
HXB2. The HIV-1 p24 antigen level was the lowest in
KRC1097, a HAART-experienced patient with anti-
retroviral drug resistance-related polymorphic sites at
D67N, K70R, T215I, K219Q, and K103R in the protein
coded by the thymidine-related drug-resistant gene.
KRB7021 with M41L, V118I, M184V, L210W, T215Y,
K219N, Y188L, and K238Q mutations related to RTIs
resistance had the next lowest p24 antigen level. On the
other hand, the pseudo-virus derived from a HAART-
naı¨ve patient showed a high level of the p24 antigen
compared with the reference strain HXB2. However,
low p24 antigen levels were not seen only in the drug-
resistant variants: isolates from the HAART-naı¨ve
patient KRC5123, also had low p24 antigen levels as did
isolates from KRB9149.
We also measured pseudo-virus infectivity using
TZM-bl cell lines. Virus infectivity was lower in drug-
resistant variants than in the reference strain HXB2. The
infectivities of homologous recombinant pseudo-viruses
were highest in the reference strain HXB2 followed by
the isolates from HAART-naı¨ve patients (KRC5180 >
KRC5123), and finally by the isolates from the HAART-
experienced patients (KRB7021 > KRB9149 >
KRC1097). In general, the antiretroviral drug-resistant
variants in this study showed lower infectivity compared
with HXB2 or isolates derived from HAART-naı¨ve
patients. This result showed that the drug-resistant HIV-
1 variants had lower infectivity and suggested that their
replication capacity in the host may be low compared
with the wild type or with the reference strain HXB2.
The isolate from KRC1097 had a T215I mutation.
Mutations at codon 215 (T215A/C/D/E/G/H/I/L/N/S/V)
are known to increase the risk of virologic failure of
AZT or stavudine in HAART-naı¨ve patients. The
T215Y mutant may emerge quickly from one of these
mutations in the presence of AZT or stavudine [16].Furthermore, a decrement in replication capacity influ-
enced by drug resistance mutations has been reported
[17]. Therefore, the low infectivity of isolates derived
from KRC1097 may be related to the revertant mutation
from T215Y to T215I as well as the thymidine analog-
associated mutations such as M41L, D67N, K70R,
L210W, T215Y/F, and K219Q/E [16]. More investiga-
tions using clinical isolates are needed to more fully
understand this effect.
In a drug-resistant variants surveillance report in
Korea, multi-nucleoside reverse transcriptase inhibitor-
resistant variants were frequently described with
mutation sites of M41L, D67N, K70R, L210W, T219Q/
E in HAART-experienced patients [6,16] and besides
M41L, D67N, and K70R, other mutation sites, L74V,
M184V, V118I, L100I and K103N, were found in
HAART-experienced HIV/AIDS patients [6]. It has also
been reported that the interaction of drug-resistant
variants affect HIV-1 replication capacity [1]; however,
this needs to be further investigated using more clinical
isolates.
For clinical isolates with no drug-resistant variants,
the variants that do exist are susceptible to antiretroviral
drugs, keeping the viral load in the blood at a low level.
However, drug-resistant variants have low infectivity
compared with the reference strain and the viral load in
the blood is expected to be high. Thus, it is supposed
that antiretroviral drug as booster for viral load or else.
Drug resistance is currently analyzed in clinical isolates
by genotypic assay based on drug treatment trends.
Thus, the present study may contribute to understanding
the viral characteristics of RT mutation strains at the
cellular level. Recently, the single cycle assay has been
used with a replication-deficient recombinant virus
containing the indicator gene (luciferase, b-galactosi-
dase) [5,13,18]. By generating site-specific mutations,
single cycle assays are expected to be used to elucidate
the effects of site-specific mutations on the viral
mechanism [14,18].
In this study, we examined the infectivity of patient-
derived pseudo-viruses in the absence of antiretroviral
drugs. For further study, we need to investigate the
differences between viral infectivity and drug suscepti-
bility in the presence of antiretroviral drugs.
Furthermore, the relationship between viral replica-
tion capacity and the RT and PR clinical mutation
variants under drug treatment condition needs to be
investigated. Such an investigation would contribute to
our understanding of the characteristics of drug-resistant
variants that arise in response to drug treatment.Acknowledgements
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